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Introduction: In Europe and beyond, the rising costs of healthcare and limited
healthcare resources have resulted in the implementation of health technology
assessment (HTA) to inform health policy and reimbursement decision-making. European
legislation has provided a harmonized route for the regulatory process with the European
Medicines Agency, but reimbursement decision-making still remains the responsibility
of each country. There is a recognized need to move toward a more objective and
collaborative reimbursement environment for new medicines in Europe. Therefore, the
aim of this study was to objectively assess and compare the national reimbursement
recommendations of 9 European jurisdictions following European Medicines Agency
(EMA) recommendation for centralized marketing authorization.
Methods: Using publicly available data and newly developed classification tools, this
study appraised 9 European reimbursement systems by assessing HTA processes and
the relationship between the regulatory, HTA and decision-making organizations. Each
national HTA agency was classified according to two novel taxonomies. The System
taxonomy, focuses on the position of the HTA agency within the national reimbursement
system according to the relationship between the regulator, the HTA-performing
agency, and the reimbursement decision-making coverage body. The HTA Process
taxonomy distinguishes between the individual HTA agency’s approach to economic and
therapeutic evaluation and the inclusion of an independent appraisal step. The taxonomic
groups were subsequently compared with national HTA recommendations.
Results: This study identified European national reimbursement recommendations
for 102 new active substances (NASs) approved by the EMA from 2008 to
2012. These reimbursement recommendations were compared using a novel
classification tool and identified alignment between the organizational structure of
reimbursement systems (System taxonomy) and HTA recommendations. However,
there was less alignment between the HTA processes and recommendations.
Allen et al. Comparing European HTA Reimbursement Recommendations
Conclusions: In order to move forward to a more harmonized HTA environment within
Europe, it is first necessary to understand the variation in HTA practices within Europe.
This study has identified alignment between HTA recommendations and the System
taxonomy and one of the major implications of this study is that such alignment could
support a more collaborative HTA environment in Europe.
Keywords: new active substances, health technology assessment, HTA, process taxonomy, system taxonomy,
reimbursement recommendations, archetypes, pharmaceuticals
INTRODUCTION
The rising cost of healthcare in the developed world, limited
healthcare resources of individual jurisdictions and the need
to improve quality and consistency of care, have resulted in
the implementation of health technology assessment (HTA)
to inform health policy and reimbursement decision making.
Generally, HTA evaluates the added therapeutic benefits and risks
for covering a health technology in the context of local standard
of care (Allen et al., 2013). In Europe, European legislation
has harmonized the regulatory process with the European
Medicines Agency now responsible for granting marketing
authorization, but reimbursement decision-making remains the
responsibility of each country (European Commission, 2004;
Allen et al., 2013). Patients also have access to a wealth of
knowledge and increased opportunities for communication and
collaboration. This increases expectations of and demands on
the healthcare system and more informed patients are now
aware of inequalities in patient access to new medicines in
different jurisdictions (Beyer et al., 2007). However, there are
also similarities between national approaches for HTA and this
could provide opportunities for a more aligned, objective, and
collaborative HTA environment in Europe (Henshall, 2012; Allen
et al., 2013).
The European Network for Health Technology Assessment
(EUnetHTA) was established in 2006 to create a sustainable
European network for HTA and to develop and implement
tools to transfer information between members (Kristensen,
2012). EUnetHTA was based on previous collaborative projects
such as EUR-ASSESS and The European Collaboration for
Health Technology Assessment (Velasco-Garrido et al., 2008).
EUnetHTA was initially granted 3 years funding from the
Abbreviations: AIFA, Agenzia Italiana del Farmaco (Italian Medicines Agency);
CADTH, Canadian Agency for Drugs and Technologies in Health; CDR, Common
Drug Review; EMA, European Medicines Agency; EPARS, European Public
Assessment Reports; EUnetHTA, European Network for Health Technology
Assessment; G-BA, Der Gemeinsame Bundesausschuss (German Federal Joint
Committee); HAS, Haute Autorité de santé (French National Authority
for Health); HTA, health technology assessment, INAMI, Institut National
d’Assurance Maladie-Invalidité (Belgian National Institute for Health and
Disability Insurance); QWIG, Institut für Qualität und Wirtschaftlichkeit im
Gesundheitswesen (German Institute for Quality and Efficiency in Healthcare);
NASs, new active substances; NCPR, National Centre for Pharmacoeconomics
(Ireland); NICE, National Institute for Health and Care Excellence (England);
REA, relative effectiveness assessment; SMC, Scottish Medicines Consortium;
TLV, Tandvårds- & läkemedelsförmånsverket (Swedish Dental and Pharmaceutical
Benefits Agency); ZINL, Zorginstituut Nederland (Netherlands National Health
Care Institute).
European Commission and the European Commission has since
supported the formation of a permanent European HTA network
with the scientific and technical cooperation of the new HTA
Network conducted by EUnetHTA through Joint Action 3 until
2020 (Kristensen, 2012; European Commission, 2013; European
Network for Health Technology Assessment (EUnetHTA),
2016). This continues EUnetHTA’s support of Article 15 of
the Directive for cross-border healthcare that requires “that
the Union shall support and facilitate cooperation between
national authorities or bodies responsible for HTA” (European
Network for Health Technology Assessment (EUnetHTA), 2016).
Meanwhile, the European Commission has initiated a process to
determine support for European HTA beyond 2020 (European
Commission, 2016a).
According to Kristensen, one of the most innovative scientific
and practical outputs of EUnetHTA has been the development
of a HTA Core Model R© that defines the key content required
for HTA to support information sharing between HTA agencies
(Kristensen, 2012). The HTA Core Model R© contains 9 domains
and each provide a framework for analysis (National Institute
for Health and Welfare, 2014): description and technical
characteristics of technology; health problem and current use
of technology; safety; clinical effectiveness; cost and economic
evaluation; ethical aspects; organizational aspects; social aspects;
and legal aspects (Figure 1). The HTA Core Model R© was
designed to enable the sharing of HTA information in a common
format that can be transferred between members at the national
and international level and the 9 domains can be split into two
groups: technical (health problem, description of technology,
safety, and clinical effectiveness) and other (economic etc.)
(Figure 1).
Pilots of the EUnetHTA HTA Core Model R© for the rapid
Relative Effectiveness Assessment (REA) focus on the technical
domains (Charles River Associates, 2015). Ascroft and Pichler
questioned the practicalities of the pilots, which resulted in the
inclusion of local and regulatory data that was considered to
be outside of the scope of the rapid REA (Ascroft and Pichler,
2014). This raised concerns that the application of the rapid
REA could introduce a duplication of effort and questioned
whether EUnetHTA members are likely to have the capacity to
extend the pilot to review all the medicines and technologies
that are reviewed by the EMA. Ascroft and Pichler (2014)
have also proposed that the rapid REA could provide value by
developing a REA report to supplement the current European
Public Assessment Reports (EPARs).
The European Commission, acknowledging the potential
benefits of increased European collaboration for HTA,
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FIGURE 1 | EUnetHTA HTA Core model® Domains.
has recently conducted a stakeholder consultation and is
undertaking an inception impact assessment for strengthening
of the EU cooperation on HTA (European Commission,
2016a). The inception impact assessment will consider
various future scenarios for EU support of HTA including:
continuing current activities until 2020; long-term voluntary
cooperation funded by the EU beyond 2020; cooperation
on collecting, sharing, and use of common data and tools;
cooperation on joint REA reports or full HTA reports and their
uptake (European Commission, 2016b). The potential for the
establishment of a pan-European HTA agency has previously
been explored by Drummond (2003), but this will require
harmonization of guidelines, decision-making and willingness
to pay.
The need for a more collaborative HTA environment has also
been acknowledged beyond Europe. Prior to 2002, Canadian
provinces and territories conducted their own assessments of
the added therapeutic benefit and cost-effectiveness of NASs
(Allen et al., 2016). The Canadian Agency for Drugs and
Technologies in Health (CADTH), Common Drug Review
(CDR) was implemented in 2002 to help standardize drug
coverage across Canada by maximizing the use of resources and
avoiding the duplication of work (Allen et al., 2016).
The need for a more collaborative HTA environment is
also acknowledged at a global level. The Sixty-seventh World
Health Assembly acknowledged the importance of regional and
international collaboration on HTA and “urges Member States:...
to consider also collaborating with other Member States’ health
organizations, academic institutions, professional associations
and other key stakeholders in the country or region in order to
collect and share information and lessons” (WHO, 2014).
There is also a recognized need to objectively describe and
classify HTA systems and two novel non-ranking taxonomies
for the classification of HTA performing agencies have been
developed and described by Allen and colleagues (Henshall,
2012; Allen et al., 2013). This study utilized these classification
methods to evaluate and compare HTA systems and processes for
reimbursement recommendations for 9 European jurisdictions
following EMA approvals for new active substances (NASs).
In a previous study, the combination of two taxonomic sets,
were used to identify different archetype groups within Europe
with a view to identifying potential groupings for collaboration
(Allen et al., 2013). The two aims of this study were to:
(1) examine the relationship between the HTA System and
Process taxonomies and the HTA recommendations for NASs
and (2) to consider whether there is opportunity for further
alignment.
METHODS
The EMA online database was searched for NASs granted
marketing authorization between January 1, 2008 and December
31, 2012. For the purpose of this study, an NAS was defined
as a chemical, biological, biotechnology, or radiopharmaceutical
substance that has not been previously available in Europe for
therapeutic use in humans and is destined to be made available as
a prescription only medicine for humans. Generics, vaccines, and
products previously licensed for sale in any European jurisdiction
were excluded from this study and only publicly available data
were used.
The initial HTA recommendations for each NAS and its
indications reviewed for reimbursement were identified from
the official national agency websites for 9 jurisdictions: Belgium,
England, France, Germany, Ireland, Italy, Netherlands, Scotland,
and Sweden. These 9 jurisdictions were selected for inclusion in
this study as they publish information on their reimbursement
assessments in the public domain and they cover a range of
taxonomies as identified in previous research (Allen et al., 2013).
Two taxonomic sets were developed by comparing HTA
process maps for 33 European jurisdictions to demonstrate the
communication and information flow pathways between the
sponsor (manufacturer) and key agencies within the national
reimbursement system (Allen et al., 2013). The System taxonomy,
focuses on the position of the HTA agency within the national
reimbursement system according to the relationship between the
regulator, the HTA-performing agency, and the reimbursement
decision-making coverage body. Five-subsets are included within
the System taxonomy (Figure 2):
S1–The regulatory, HTA and coverage body functions are
performed by separate agencies
S2–The regulatory and HTA functions are performed by a single
agency and the coverage body functions are independent
S3–The HTA and coverage body functions are performed
by a single agency with the regulatory function performed
independently
S4–The regulatory, HTA and coverage body functions are all
performed within a single agency
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FIGURE 2 | The System taxonomy includes five subsets and is based on the
position of three core functions: a national HTA performing agency, if present,
in relation to the position of the regulatory authority (REG) and the
decision-making coverage body (CB). The five-subset of the System
taxonomy: S1–the regulatory, HTA and coverage body functions are performed
by separate agencies. S2–the regulatory and HTA functions are performed by
a single agency and the coverage body functions are independent. S3–the
HTA and coverage body functions are performed by a single agency with the
regulatory function performed independently. S4–the regulatory, HTA and
coverage body functions are all performed within a single agency. S5–no HTA
is performed within the national regulatory to reimbursement system.
S5–No HTA is performed within the national regulatory to
reimbursement system
The interactions between the three core functions of the System
taxonomy can ultimately affect overall system performance.
Drummond et al. (2008) have stressed the importance of
conducting HTA independently of the decision-making body to
reduce bias, and this System taxonomy permits the classification
of jurisdictions based on the independence of the HTA process.
The HTA Process taxonomy distinguishes between the
individual HTA agency’s approach to economic and therapeutic
evaluation and the inclusion of an independent appraisal step.
Four-subsets were identified for the HTA Process taxonomy
(Figure 3):
H1–The therapeutic value assessment, economic evaluation and
appraisal are performed within the same agency
H2–The therapeutic value assessment is conducted within the
same agency as Economic evaluation but the appraisal is
performed independently, usually by health professionals rather
than civil servants
H3–The therapeutic value is assessed prior to independent
appraisal
H4–The appraisal is conducted using information from an
external HTA report or by considering the coverage decisions
of reference countries.
The inclusion of an independent appraisal step can reduce
the perception of bias and is therefore an important factor
that should be considered for the purpose of classification
(Drummond et al., 2008). However, not all agencies adopt this
approach for medicines and may conduct their own assessment
as it is the manufacturer’s dossier that is submitted for appraisal.
Each HTA recommendation or reimbursement decision was
categorized as, recommended, recommended with restrictions, or
FIGURE 3 | The HTA process taxonomy includes four subsets and focuses on
the key tasks performed by the HTA agency. Each group shows the relative
positions of three key tasks, if performed, within the HTA agency: therapeutic
value (TV), economic value (EV), and appraisal (AP). The four-subsets of the
HTA Process taxonomy: H1–the therapeutic value assessment, economic
evaluation and appraisal are performed within the same agency. H2–the
therapeutic value assessment is conducted within the same agency as
Economic evaluation but the appraisal is performed independently, usually by
health professionals rather than civil servants. H3–the therapeutic value is
assessed prior to independent appraisal. H4–the appraisal is conducted using
information from an external HTA report or by considering the coverage
decisions of reference countries.
not recommended. These three HTA recommendation categories
were subsequently numerically coded for direct comparison
between agency pairs to enable identification of the total
number of aligned recommendations. For each pair of agencies
(jurisdictional pairs), the total number of medicine—indication
pairs reviewed by both agencies were identified and the
proportion of congruent recommendations were calculated
by percentage agreement. The percentage agreements for
jurisdictional pairs that were allocated to the same taxonomic
subsets were compared with the percentage agreements for
jurisdictional pairs from different subsets to identify potential
alignment.
RESULTS
Comparison of HTA Recommendations by
9 European HTA Agencies
A total of 102 NASs received a central marketing authorization
in accordance with regulation 726/2004 between January 1,
2008 and December 31, 2012 (European Commission, 2004).
However, the reimbursement information available for these
NASs varied between agencies, as only data available in the
public domain by August 2014 were used (Table 1). The
HTA reimbursement recommendations for the 9 European
jurisdictions included in the study are shown in Figure 4.
Reimbursement recommendations for England were available
for 39% of the NASs included in this study, as the National
Institute for Health and Care Excellence (NICE) only conduct
appraisals for NASs expected to have a “significant impact”
(National Institute for Health and Care Excellence (NICE),
2017). Medicines that are not reviewed by NICE can be
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FIGURE 4 | Number of HTA reimbursement recommendations for 9 European jurisdictions classified according to recommendation category.
considered for reimbursement through NHS England or
Clinical Commissioning Groups. The publically available
recommendations from the German Federal Joint Committee
(G-BA) early benefit assessment are only available from
January 1, 2011, which was reflected in their low number of
recommendations. In contrast with the other jurisdictions, all
recommendations issued by the G-BA have been allocated to the
universal reimbursed category; this difference occurs because
the G-BA recommendation only gives a score for the added
therapeutic benefit to inform price negotiations. Reimbursement
recommendations from The French National Authority for
Health (HAS) also provide a score for added therapeutic benefit,
but recommendations can also include restrictions or a rejection
of the application.
In Ireland, no outcome was recorded when there was only a
recommendation to conduct a full pharmacoeconomic review. In
addition, the assessment information available in Ireland did not
include a category that could be classified as restricted. In Italy,
NASs are reviewed by the Italian Medicines Agency for inclusion
in their national formulary. This formulary includes three lists;
List A for fully reimbursed products; List H for products only
reimbursed in hospitals and List C for products not reimbursed
(Italian Medicines Agency (AIFA), 2015). Only two of these
lists were available online at the time of this study and neither
list included approved indications or criteria for prescribing.
Due to the ambiguity of these recommendations, Italy has
been excluded from the final comparisons. Also excluded
from the comparisons were the negative recommendations of
the Scottish Medicines Consortium (SMC), which are made
when sponsors (manufacturers) of a NAS fail to submit a
dossier for review (Scottish Medicines Consortium (SMC),
2012). Positive recommendations for reimbursement by the
Netherlands National Health Care Institute (ZiNL) can be
categorized into two groups: Annex 1a for NASs that have a
similar therapeutic value and are interchangeable and Annex 1b
for NASs that have added therapeutic value.
The reimbursement decision pathways for NASs vary across
the 9 jurisdictions compared in this study (including Italy)
(Allen et al., 2013). They all involve input from the sponsor and
communication between the market authorities: the regulator,
the pricing authorities, the recommender, and the decisionmaker
within each jurisdiction. For example, NICE conducts horizon
scanning and receives requests from the Department of Health to
identify potential NASs for review.
Comparison of HTA Recommendations
and Taxonomic Classifications
A total of 28 unique jurisdictional pair combinations and
their congruence (percentage agreement) were evaluated and
displayed in a cross tabulation format (Tables 2, 3). These 28
pairs present the proportion of congruent recommendations for
the total number of medicines reviewed by both jurisdictions.
The congruence percentages have been classified into three
grades: high congruence (≥75%); medium congruence (≥ 50%
to 74%); and low congruence (<50%). In each table, the
jurisdictions were grouped according to their respective subsets
within each of the two taxonomies (Figures 2, 3). For the
System Taxonomy, the S1 set includes Germany, Ireland, France,
Netherlands, and Belgium and the S3 set includes England,
Scotland, and Sweden. None of the jurisdictions reviewed were
classified as S2, S4, or S5 (Table 2). For the HTA process
taxonomy, the H1 subset includes Scotland, Ireland, and Sweden;
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TABLE 2 | Alignment of HTA recommendations and reimbursement decisions allocated to three categories by the System taxonomy.
System 
taxonomy 
subsets
Alignment of HTA 
recommendations (number of 
products reviewed) 
Ireland France Netherlands Belgium England Scotland Sweden
S1
Germany 54% (24) 93% (30) 76% (25) 96% (24) 60% (15) 33% (21) 31% (16)
Ireland 54% (50) 51% (47) 67% (42) 55% (29) 51% (49) 33% (42)
France 79% (72) 88% (68) 58% (38) 26% (74) 46% (57)
Netherlands 81% (57) 63% (35) 43% (63) 54% (54)
Belgium 68% (31) 23% (60) 54% (46)
S3
England 45% (38) 53% (30)
Scotland 50% (56)
Sweden
Congruence Key
High congruence ≥ 75% Medium congruence < 75% to ≥ 50% Low congruence <50%
For the System Taxonomy sets outlined, the S1 set includes Germany, Ireland, France, Netherlands, and Belgium and the S3 set includes England, Scotland, and Sweden. None of the
jurisdictions reviewed were classified as S2, S4, or S5.
TABLE 3 | Alignment of HTA recommendations and reimbursement decisions allocated to three categories by the HTA Process taxonomy.
HTA Process 
taxonomy
subsets
Alignment of HTA 
recommendations (number of 
products reviewed) 
Belgium Scotland Ireland Sweden France Netherlands Germany
H2
England 68% (31) 45% (38) 55% (29) 53% (30) 58% (38) 63% (35) 60% (15)
Belgium 23% (60) 67% (42) 54% (46) 88% (68) 81% (57) 96% (24)
H1
Scotland 51% (49) 50% (56) 26% (74) 43% (63) 33% (21)
Ireland 33% (42) 54% (50) 51% (47) 54% (24)
Sweden 46% (57) 54% (54) 31% (16)
H3
France 79% (72) 93% (30)
Netherlands 76% (25)
Germany
Congruence Key
High congruence ≥ 75% Medium congruence < 75% to ≥ 50% Low congruence <50%
For the HTA process taxonomy sets outlined, the H1 set includes Scotland, Ireland and Sweden; the H2 set includes England and Belgium and the H3 set includes Germany, France
and the Netherlands. None of the jurisdictions reviewed were classified as H4 taxonomy.
the H2 set includes England and Belgium and the H3 subset
includes Germany, France, and the Netherlands. None of the
jurisdictions reviewed were classified as H4 taxonomy (Table 3).
Overall, six of the country pair comparisons displayed
high-level congruence (Belgium paired with Germany, France,
or Netherlands, Germany paired with Netherlands or France
and France paired with Netherlands). The strongest alignment
(≥88%) was observed between Belgium, France, and Germany,
which could be due to these agencies focus on therapeutic
benefit (Figures 5–8). All six pairs are also located within the
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FIGURE 5 | Process maps for Belgium.
S1 taxonomic group, which is the largest group within the
System taxonomy and represents a system that has separate
agencies or organizations to perform the regulatory, HTA and
decision-making functions (Table 2, Figure 2). All jurisdictional
pairs within this S1 taxonomic group had a 50% or higher
agreement for HTA recommendations and therefore scored
either high or medium congruence. Taxonomic set S3 (England,
Scotland, and Sweden) did not include any high congruence pairs
and only included two medium and one low congruence pair.
These 28 jurisdictional pairs were arranged in a second cross
tabulation in which jurisdictions were grouped according to
their Process taxonomy (Table 3, Figure 3). The two jurisdictions
in HTA process taxonomic group H2 (England, and Belgium)
perform the therapeutic value and economic value assessment
with an independent appraisal and scored medium congruence.
Group H1 (Scotland, Ireland, and Sweden) scored two medium
congruent pairs and one low congruent pair (Sweden and
Ireland). Taxonomic group H3 included Germany, France and
Netherlands with all three jurisdictional pairs presenting high
congruence with a percentage agreement ranging from 76 to
93%. The distribution of high, medium-, and low-congruence
pairs indicates alignment around the H3 subset, but does not
indicate any clustering around the other HTA Process taxonomic
groupings.
DISCUSSION
In order to move forward to a more harmonized HTA
environment within Europe, it is first necessary to understand
the variation in HTA practices there. The processes required for
providing patients’ access to new medicines has become more
complex with the increased uptake of HTA to inform coverage
decisions. Obtaining reimbursement is commonly referred to
as the “fourth hurdle,” as this can require a positive HTA
recommendation based on the relative clinical benefit and
cost effectiveness of a new health technology following the
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FIGURE 6 | Process map for France.
regulatory assessment for safety, efficacy, and quality, while
some also note a fifth hurdle: affordability. The European
Union’s establishment of the EMA successfully standardized
the procedure for the review and approval of new medicines
across Europe in accordance with regulation 726/2004 (European
Commission, 2004). However, the pharmaceutical industry is
still required to submit multiple applications to individual
European countries for HTA and reimbursement assessments,
which can result in varying reimbursement recommendations.
Discrepancies between HTA recommendations may also be
due to the quality of evidence available, willingness to accept
uncertainty or differing methods of assessment or priorities
(Allen et al., 2017). The methodologies and processes used
to conduct HTA can vary from country to country and
also between regions when decision making is decentralized
(e.g., Italy and Spain). Thus, the pharmaceutical industry
must learn to navigate an ever-changing patchwork of HTA
agencies, as HTA methodologies and processes continue to
evolve.
Manufacturers often submit applications first to markets
where they are likely to achieve a higher price, as reasoned by
Morton and Kyle (2012):
“...a manufacturer should want to negotiate over prices and launch
new products in high-price countries first, so as to positively affect
any reference price used by later countries.”
Many European countries will review prices achieved in other
European markets to guide pricing. The regulation of drug prices
varies between markets and this is taken into consideration when
launching new medicines:
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FIGURE 7 | Process map for Germany.
“...the price on these markets is usually higher due to the lack of the
regulation and it is therefore more profitable for the manufacturers
to market the drugs in these countries first” (Łanda et al., 2009).
This can result in patient access inequalities throughout Europe,
as patients in countries that tend to pay higher prices are more
likely to have earlier access, while patients in countries that are
unable or not willing to provide coverage at a price obtained in
other European countries may be denied access:
“Studies concluded that pharmaceutical firms had incentives in
launching new drugs in high-price countries first and delaying
launch or even not launching new drugs in low-price countries”
(Toumi et al., 2014).
The time taken to prepare multiple submissions is also
detrimental to the pharmaceutical industry as it reduces the
time remaining with patent protection to recover research and
development costs and generate a profit.
The results of this research highlight the varying approaches
to HTA and the potential impact this can have on the
reimbursement of new medicines. For example, the proportion
of the 102 NAS Medicine-indication pairs reviewed by a single
agency ranges from 30% (Germany) to 91% (France). The low
proportion of recommendations reviewed by the German G-BA
is due to the implementation of the new AMNOG requirements
during the study period (Ruof et al., 2014). However, the 39%
of medicines reviewed by NICE (England) is due to the agency’s
mandate to only reviewmedicines of significant impact (National
Institute for Health and Care Excellence (NICE), 2017). This
is very different to other agencies that require a HTA for all
new medicines, such as France and Scotland. The proportion
of medicines reviewed is also dependent on the manufacturer’s
decision to submit a HTA dossier for review.
This study has evaluated the relationship between HTA
agencies’ recommendations, their classification into taxonomic
sets and calculated the percentage agreement for all 28 possible
combinations of jurisdictional pairs. The percentage agreement
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FIGURE 8 | Process map key.
results demonstrate alignment between HTA recommendations
and the System taxonomy. However, the results demonstrate less
alignment between HTA recommendations and HTA Process
taxonomic sets. This could be due to the diversity of the decision
making processes and the heterogeneity of the systems compared,
but may also suggest that further research is required to refine
the archetypes for real-life application. It is also more difficult
to allocate agencies to HTA Process taxonomic sets because it
is not always clear how independent the clinical evaluation is
from the economic evaluation. For example, the French National
Authority for Health (HAS) now requires the submission of
an economic dossier in parallel with the clinical submission,
but only for NASs that have a high rating for improvement
in medical benefit (ASMR I, II, or III) and an estimated total
cost to the system of more than €20 million within 2 years
of commercialization (Haute Autorité de Santé (HAS), 2015).
Therefore, the HAS evaluation could be allocated to different
HTA Process taxonomic sets, depending on the NAS evaluated.
Comparison with Similar Studies
The comparisons of eight European HTA agencies in this
study, build on previous research by Nicod and Kanavos
(2012) and Bending et al. (2012). Nicod and Kanavos evaluated
HTA recommendations from Australia, Canada, England,
Scotland, and Sweden with a particular focus on therapeutic
areas and identified significant variation between national
recommendations. Bending et al. compared the processes and
recommendations of two national HTA agencies (France and
Scotland) to identify differences between agencies that include
or exclude cost-effectiveness evaluations for reimbursement
recommendations for new medicines. However, there are many
factors that can cause discordant HTA recommendations and
comparing only two agencies has limited value. Therefore, the
comparisons of HTA recommendations from eight European
HTA agencies are more likely to identify potential alignment
of factors that impact reimbursement recommendations. The
calculations for agreement between country pairs indicated that
HTA agencies, classified by the System taxonomy,might correlate
with concordant HTA recommendations. This is a novel result
and a valuable outcome of the development of the taxonomies as
a classification tool, with the implication from this study that such
alignment could support a more collaborative HTA environment
in Europe.
Is There Potential for a More Aligned HTA
Environment in Europe?
The establishment of the CDR in Canada has demonstrated a
successful working model for sharing HTA evidence derived
from a centralized review, to provide a more efficient use of
resources to support regional decision making (Allen et al., 2016)
Similarly, there is a general acceptance that decision making
should remain at the national/local level in Europe, but this does
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not prevent collaborations for assessment (Kleijnen et al., 2015).
The rationale underpinning the establishment of EUnetHTA has
similarities with the rationale for the creation of the CDR, as
both aim to reduce duplication of work, use HTA resources
more efficiently, and provide access to robust scientific evidence.
The disparities between medicines coverage across Canadian
provinces was a key concern that led to the development
of the CDR to provide a standard approach to HTA that
could inform regional decisions (Allen et al., 2016). European
countries are more heterogeneous than Canadian provinces
and territories, but similar concerns have been raised regarding
varying patient access to new medicines and EUnetHTA aims
to support cross-border application of tools and methodologies
for HTA (European Network for Health Technology Assessment
(EUnetHTA), 2016).
Drummond (2003) argued that the creation of a European
HTA agency is a possibility but three key challenges would need
to be harmonized first: economic evaluation guidelines, decision-
making processes, and societal willingness-to-pay for health
technologies. He suggested that the harmonization of economic
guidelines would be the easiest of the three challenges, but
even with common European guidelines the differences between
country policies may require tailored reports to enable inclusion
or exclusion of data, such as productivity costs. Harmonizing
societal willingness-to-pay is arguably the most challenging
factor. Even if there were a single price for Europe, there would
still be differences in the local costs for healthcare that may
be required to deliver or monitor the medicine, which would
affect the cost-effectiveness of the product. Overall, Drummond
suggests the likelihood of all three achieving harmonization in the
near future is very low.
Overall, there are two key aspects of the reimbursement
decision that should be considered for evaluating the potential
for harmonization: the technical evaluation and the final
reimbursement decision. The safety and clinical effectiveness of
a new medicine is a technical consideration that is relevant for
all reimbursement decisions. However, the added therapeutic
benefit of a newmedicine is dependent on the chosen comparator
and will impact the final reimbursement decision. Similarly, as
proposed by Drummond (2003) HTA agencies that consider
cost-effectiveness could align the economic guidelines, but the
local costs considered and willingness to pay will be specific
for each jurisdiction and thus difficult to harmonize the final
decision. This study has evaluated the final reimbursement
recommendation that considersmore variables than the technical
evaluation and identified alignement within certain taxonomic
subsets. Therefore, one could assume that there could be greater
alignment between the less variable technical evaluation and this
is where initial collaboration efforts should focus. The European
Commission’s inception impact assessment on the strengthening
of the EU cooperation on HTA will be exploring various options
for European HTA collaboration at the end of 2017 (European
Commission, 2016b).
A pan-European HTA agency is a controversial topic and
it could be argued that it is not possible to harmonize HTA
across Europe, as the countries are too different with respect
to healthcare budgets and medical standards of care together
with the political, social, and economic aspects of HTA, which
are difficult to align. However, the Canadian HTA environment
provides a working model for a centralized HTA agency that
enables regions to include evidence generated at the national
level that has been considered in the local context (Allen et al.,
2016). It should also be noted that prior to the establishment
of the EMA there were many who doubted the possibility
of a single European regulatory authority, due to varying
approaches across Europe. However, the EMA was established
in 1995 and has now been successfully providing marketing
authorization for medicines across Europe for more than
20 years.
Limitations and Future Research
The two taxonomic sets have been used to compare HTA
recommendations from eight European national agencies
(excluding Italy). The number of HTA agencies included
for comparison was limited due to the varied depth of
information published online and the agencies included are
fairly homogenous in regards to their economic development.
Further, it was not possible to have a range of jurisdictional
pairs for all taxonomic groupings, as HTA reimbursement
recommendations were only compared for eight agencies. The
HTA Process taxonomy contains at least two countries with
national HTA recommendations for comparison (jurisdictional
pairs) for all three of the HTA performing taxonomic sets;
however, the “System taxonomy” does not contain any pairs
for two of the four HTA performing taxonomic sets (S2 and
S4) and this is a limitation for this study. Future studies could
expand on this research by including at least two national
HTA agencies for all HTA performing taxonomic sets and by
comparing HTA recommendations over a longer period of time
to identify trends. Comparing reimbursement recommendations
across agencies with varying processes is challenging and this
study grouped the different reimbursement recommendation
options into three main groups (reimbursed, reimbursed with
restrictions, and not reimbursed) to facilitate comparison. Not all
agencies included in this study issue recommendations that fall
within all three categories and this is a limitation to this research.
The final reimbursement decision may also be influenced by
the submitted price and whether an agency has a mandate to
negotiate price or consider a managed entry agreement to share
the financial risk. This was not a consideration in this study
and future research could augment this study by evaluating
the impact of price and managed entry agreements for HTA
recommendations.
CONCLUSION
This research has identified alignment between HTA
recommendations and the System taxonomy, but less
alignment was identified with the HTA process taxonomy.
Therefore, it could be argued that there is a relationship
between the regulatory, HTA, and decision-making functions
in the healthcare system and the final HTA reimbursement
recommendations, but further research would be needed to
support this relationship. Understanding the disparities in HTA
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practices within Europe and the impact of these variations
on patient access is necessary to move forward to a more
harmonized HTA. Therefore, one of the major implications
of this study is that such alignment could support a more
collaborative HTA environment in Europe.
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